Literature DB >> 22926520

Src family kinases mediate cytoplasmic retention of activated STAT5 in BCR-ABL-positive cells.

N Chatain1, P Ziegler, D Fahrenkamp, E Jost, R Moriggl, H Schmitz-Van de Leur, G Müller-Newen.   

Abstract

Persistent activation of the Abl tyrosine kinase in the BCR-ABL fusion protein is the major cause of chronic myeloid leukemia (CML). Among many other substrates BCR-ABL phosphorylates STAT5 and Src family kinases (SFK). Activated pSTAT5 is essential for initial transformation and maintenance of the disease. Cytokine-induced phosphorylation on tyrosine 694 typically leads to nuclear accumulation of pSTAT5 and target gene expression. We verified that in BCR-ABL-positive progenitor cells from a CML patient and in K562 cells pSTAT5 is cytoplasmic. However, upon ectopic expression of BCR-ABL p210 in non-myeloid cells, co-transfected STAT5A is phosphorylated on Y694 and localized in the nucleus arguing for an additional factor mediating cytoplasmic retention in CML cells. Expression of the SFK v-Src, Hck or Lyn together with STAT5A results in phosphorylation on Y694 and cytoplasmic retention. Upon coexpression of BCR-ABL and individual SFK the cytoplasmic retention of activated STAT5A mediated by v-Src and Hck but not Lyn is dominant over nuclear translocation induced by BCR-ABL. Cytoplasmic retention depends on the kinase activity of SFK and is mediated through the interaction of the SH2 domain of STAT5A with the SFK. Interestingly, nuclear accumulation of STAT5A as a result of activation by FLT3-ITD, an oncogene found in acute myeloid leukemia, cannot be prevented by coexpression of SFK. Importantly, inhibition of SFK in K562 cells restored nuclear accumulation of pSTAT5A, enhanced STAT5 target gene expression and increased colony formation. Thus, SFK mediate cytoplasmic retention of pSTAT5A in BCR-ABL-positive cells. Cytoplasmic pSTAT5A in CML cells might balance the controversial functions of STAT5 in cellular senescence and differentiation versus G1/S progression and survival.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22926520     DOI: 10.1038/onc.2012.369

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  18 in total

Review 1.  Protein tyrosine phosphatases as wardens of STAT signaling.

Authors:  Frank-D Böhmer; Karlheinz Friedrich
Journal:  JAKSTAT       Date:  2014-02-20

Review 2.  Signal transducer and activator of transcription (STAT)-5: an opportunity for drug development in oncohematology.

Authors:  Carlota Recio; Borja Guerra; Miguel Guerra-Rodríguez; Haidée Aranda-Tavío; Patricia Martín-Rodríguez; Mercedes de Mirecki-Garrido; Yeray Brito-Casillas; José M García-Castellano; Ana Estévez-Braun; Leandro Fernández-Pérez
Journal:  Oncogene       Date:  2019-02-19       Impact factor: 9.867

Review 3.  Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy.

Authors:  Siham Bibi; Melis Dilara Arslanhan; Florent Langenfeld; Sylvie Jeanningros; Sabine Cerny-Reiterer; Emir Hadzijusufovic; Luba Tchertanov; Richard Moriggl; Peter Valent; Michel Arock
Journal:  Haematologica       Date:  2014-03       Impact factor: 9.941

4.  Stat5 Exerts Distinct, Vital Functions in the Cytoplasm and Nucleus of Bcr-Abl+ K562 and Jak2(V617F)+ HEL Leukemia Cells.

Authors:  Axel Weber; Corina Borghouts; Christian Brendel; Richard Moriggl; Natalia Delis; Boris Brill; Vida Vafaizadeh; Bernd Groner
Journal:  Cancers (Basel)       Date:  2015-03-19       Impact factor: 6.639

5.  Effects of a Particular Heptapeptide on the IFN-α-Sensitive CML Cells.

Authors:  Fu-Lan Yang; Fang-Zhi Chen; Xin-Xing Wan; Xi Zhou; Mei-Juan Zhou; Han-Chun Chen; Jun-Jiang Fu; Dian-Zheng Zhang
Journal:  Biomed Res Int       Date:  2015-09-01       Impact factor: 3.411

Review 6.  Hematopoietic cell kinase (HCK) as a therapeutic target in immune and cancer cells.

Authors:  Ashleigh R Poh; Robert J J O'Donoghue; Matthias Ernst
Journal:  Oncotarget       Date:  2015-06-30

7.  Induction of apoptosis by directing oncogenic Bcr-Abl into the nucleus.

Authors:  Zheng-Lan Huang; Miao Gao; Qian-Yin Li; Kun Tao; Qing Xiao; Wei-Xi Cao; Wen-Li Feng
Journal:  Oncotarget       Date:  2013-12

Review 8.  STAT5 acetylation: Mechanisms and consequences for immunological control and leukemogenesis.

Authors:  Christian Kosan; Torsten Ginter; Thorsten Heinzel; Oliver H Krämer
Journal:  JAKSTAT       Date:  2013-08-19

9.  NOX4-driven ROS formation mediates PTP inactivation and cell transformation in FLT3ITD-positive AML cells.

Authors:  A K Jayavelu; J P Müller; R Bauer; S-A Böhmer; J Lässig; S Cerny-Reiterer; W R Sperr; P Valent; B Maurer; R Moriggl; K Schröder; A M Shah; M Fischer; S Scholl; J Barth; T Oellerich; T Berg; H Serve; S Frey; T Fischer; F H Heidel; F-D Böhmer
Journal:  Leukemia       Date:  2015-08-26       Impact factor: 11.528

10.  PAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesis.

Authors:  A Berger; A Hoelbl-Kovacic; J Bourgeais; L Hoefling; W Warsch; E Grundschober; I Z Uras; I Menzl; E M Putz; G Hoermann; C Schuster; S Fajmann; E Leitner; S Kubicek; R Moriggl; F Gouilleux; V Sexl
Journal:  Leukemia       Date:  2013-11-22       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.